Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.

Huilin TangDandan LiJingjing ZhangYufeng LiTiansheng WangSuo-di Zhai Yiqing Song

Published in: Diabetes, obesity & metabolism (2017)

The present meta-analysis indicated that dapagliflozin may increase the risk of adverse renal events, while empagliflozin may have a protective effect among patients with T2DM. Further data from large well-conducted randomized controlled trials and a real-world setting are warranted.

Keyphrases

systematic review
meta analyses
randomized controlled trial
big data
adverse drug
emergency department
adipose tissue
metabolic syndrome
artificial intelligence
network analysis